Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Income from Continuing Operations (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Income from Continuing Operations for 6 consecutive years, with 56855000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 29.68% to 56855000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 209141000.0, a 45.83% decrease, with the full-year FY2024 number at 160791000.0, down 59.74% from a year prior.
  • Income from Continuing Operations was 56855000.0 for Q3 2025 at 4D Molecular Therapeutics, down from 54597000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7589000.0 in Q2 2021 to a low of 56855000.0 in Q3 2025.
  • A 5-year average of 31557578.95 and a median of 28663000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: soared 60.71% in 2023, then crashed 334.17% in 2024.
  • 4D Molecular Therapeutics' Income from Continuing Operations stood at 25076000.0 in 2021, then decreased by 9.2% to 27382000.0 in 2022, then fell by 17.85% to 32271000.0 in 2023, then tumbled by 53.85% to 49650000.0 in 2024, then dropped by 14.51% to 56855000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Income from Continuing Operations are 56855000.0 (Q3 2025), 54597000.0 (Q2 2025), and 48039000.0 (Q1 2025).